Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
The drug was approved by the FDA on February 17 ahead of the decision date, which was February 28. Lad presented the 2-year results of pegcetacoplan from the DERBY and OAKS trials earlier in February at the Angiogenesis, Exudation, and Degeneration 2023 meeting. She explained then that the drug’s effect to slow disease progression increases over time as patients take the drug for longer.
Transcript
Geographic atrophy is a huge clinical unmet need that has had no answers in the past, we've had no previously approved options. Speaking to the experience of a patient living with geographic atrophy, I can tell you, it's really debilitating when it becomes severe. I had a patient the other day, they told me, “I would walk to the end of the world to get any information about trials or any way to get help.” Not even a treatment, but anything in the pipeline. So, for this type of patient—and there are many—any approved treatment is a dream come true.
Now that we have this approval, it's the beginning of a treatment of a major disease. We didn't have this option the past, and we're very grateful. It's a really exciting first treatment for geographic atrophy, a really exciting time for drying [age-related macular degeneration] as a space. And I'm looking forward to beginning the treatment of GA patients in the future.
This will give the patient's renewed hope that they'll be able to do everything they enjoy doing, see their family members, and live a fulfilling life.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More